The key selling points of the leading project must be thoroughly explained today.

Original 91 Qin Shifu, Wall Street Command Center, April 7, 2026, 11:22

Lots of people in Hebei, the moment they see disagreements at the high end today, only have one sentence left in their heads: [Taoguba]

Should I run?

Wrong.

A huge mistake.

The people who truly trade as leaders never look at “whether it shook today,” nor “whether it’s already surged a lot,” and not even “whether I’m scared watching it.”

What they truly look at is always just one thing:

Does this sector still have anyone continuing to push forward today?

If there’s still a first board.

If there are still little brothers helping out.

If there are still elastic names moving in sync upward.

Then it means one thing:

The main theme hasn’t died yet, and the leader isn’t at the point where you should draw the real conclusion.

Today, this article will lay out this question completely and clearly.

Why did we keep seeing the medical sector correctly?

What exactly is the real selling point of the leader?

Why are even the biggest divergences on consecutive limit-ups nothing to be afraid of?

And also, why me circling a certain first-board doesn’t mean I’m saying “go buy the next one.”

Today I’ll make all these questions clear in one go.

First, say the conclusion first: the medical line has not finished yet, and up to now it’s still not done.
Second, our view on medical has continued to be validated by the market.
Third, the leader’s true selling point is not “it has gone up too much,” but “the sector is no longer spreading.”
Fourth, players using different models really don’t need to force discussion, because they’re not even looking at the same point.

On today’s tape, why is medical still considered strong? Don’t beat around the bush—just look at the most core information in your screenshot.

From the Tonghuashun sector page, the innovative drugs sector was red at the time, and the sector index was +1.18%.

From the sector constituent stocks, the front row isn’t only propped up by a single high banner.

Let me break it down for you directly:

Pay attention to the key point.

Today’s most important thing is not “JinYao Pharmaceutical hit another board.”

Instead, it’s:

This first-board from Xintian Pharmaceutical was pulled out by funds.

What does that mean?

It doesn’t mean “go blindly buy Xintian Pharmaceutical next.”

It means:

Within the medical sector today, there are still people continuing to pull first boards.

This sentence is extremely important.

Because it directly determines how you should look at the leader.

Why did I circle Xintian Pharmaceutical? It’s not to make you buy it—today I’m going to explain this point smoothly.

In the group, there are always people who private message me:

“By circling this, is it the next one to buy?”

“Are you implying this one is next for relay?”

“Can this stock go?”

None of these.

The fact that I circled it isn’t an instruction.

I circled it to observe the sector.

Many people who trade always can’t tell these two layers apart:

One is the execution layer of an individual stock.

One is the sector validation layer.

If you mix these two things together, trading will always go wrong.

Today I circled Xintian Pharmaceutical, and what I’m trying to express is only one sentence:

In the medical sector, first boards are still being pulled.

As long as there are still first boards being pulled in the sector, what does that indicate?

It indicates the sector is still spreading internally.

It indicates that incremental funds aren’t locked solely into JinYao Pharmaceutical.

It indicates this line hasn’t entered the truly “solitary leader” stage in a real sense.

It indicates the leader isn’t at the end-state where “the whole sector is wiped out, and only it is still hard-pushing.”

So you need to understand this:

I’m circling a sector strength signal.

Not a buy point notification.

Not even intraday call orders.

Why is medical called “still correct”? Today I have to be direct.

In the past few days, we kept saying: medical isn’t a one-day pulse. It’s not something that disappears after a news trigger. It’s not just random bluster—it’s being continuously reinforced.

Now you can see the market’s answer is very clear:

This judgment is still being validated.

Why am I confident to say that?

Because a truly strong line isn’t judged by how many limit-ups happen on just one day.

You need to see whether it can go through the following stages:

The first wave—an identifiable stock comes out first
There’s divergence in the middle, but the high banner doesn’t die
After the divergence, there are new follow-through stocks, including first-board assists
The sector can keep maintaining人氣 (buzz), not just a one-day trip

That’s what medical is going through right now.

At the beginning, Meinuo Pharmaceutical first lifted the buzz for this line.

Then JinYao Pharmaceutical took over the space and the identifier.

And now, within the sector, first boards are still popping up, elastic names are still moving with it, and front-row names are still keeping the temperature.

This is called:

Not getting it right just one day.

But being validated by the market day after day for several days.

The biggest mistake many people make is they only look one day at a time.

Today it’s strong, so they shout “strong!”

Tomorrow it diverges, so they shout “it’s over.”

The day after tomorrow it returns, and then they start chasing again.

That isn’t trading.

That’s just emotions following the K-line.

The leader’s true selling point—first: within the sector there are no longer first-board limit-ups, and the little brothers have no assists. I’ll put this first.

Because this is the most important sentence today.

The leader’s true selling point isn’t “it’s gone up too much.”

The leader’s true selling point is when it starts losing the sector.

What does that mean?

You look at it and think the boards are still pretty fierce.

But when you look back, there are:

No first boards.

No second-board follow-through.

No little brothers jumping in.

The mid-band doesn’t move.

The elastic names lie flat.

Except for itself, the whole sector shows no response.

That’s when it becomes dangerous.

Because the leader isn’t a god.

The leader also needs the sector to take over the emotion, spread the money-making effect, and digest its own high-position selling pressure.

Once the sector is gone, the leader easily shifts from “market’s emotional leader” to “the last one holding the baton crowding together.”

So why is today’s first-board from Xintian Pharmaceutical important?

Because it doesn’t decide whether you buy it or not.

What it decides is:

JinYao Pharmaceutical is not yet a pure isolated single-board.

This medical line is still spreading today.

That is the core of the leader-selling-point judgment.

It’s not about whether you feel scared in your heart.

It’s not about how much profit is in your account.

It’s about:

Is there still anyone in the sector continuing to push forward?

The leader’s true selling point—second: big divergence after consecutive limit-ups is normal. If you’re trading as a leader, you need a strong stomach—many people hear this and think it’s like a chicken soup quote.

But it’s not.

This is pure trading reality.

When you’re a leader trader, what can’t you be afraid of the most?

You can’t be afraid of divergence.

Because if the leader never diverges the whole way, that would actually be abnormal.

A truly high banner, if it goes on to the later stage, will definitely have big shakeouts, definitely someone will smash it, definitely there will be heavy turnover, and definitely someone will doubt whether it’s reached the end.

That’s the leader.

If it doesn’t go like that, how do you filter people?

You have to understand: the leader was never meant to let everyone feel comfortable making money.

It must go through strong divergence.

It must shake off people who don’t have enough confidence.

It must scare away back-row thinking.

It must make the market confirm again and again: “Who is really the strongest?”

So why do many people never make it up to the leader?

It’s not because they don’t know who the leader is.

It’s because they can’t accept leader divergence.

In their mind, they always think:

“After going up so much, it doesn’t feel good.”

“Why does it shake so terribly?”

“Could it be topping?”

“Maybe I should buy a low-position lagging rebound stock instead.”

And then the result is:

The leader goes up even more, but falls more slowly.

The back row doesn’t go up much, but once it falls, it falls brutally.

That’s the root of why most people repeatedly end up losing.

To trade as a leader, you need a strong heart.

If you don’t have this psychological preparation, don’t touch high-position core names.

The moment you touch it, once divergence comes, everything gets messy.

The leader’s true selling point—third: the cycle is usually about two weeks; don’t decide life or death based on a single day—that’s something most people easily ignore.

Many people look at the main line, and they only have two states:

Either they think it’s just starting and can go on forever.

Or they think that once there’s divergence, today is over.

Both are wrong.

The normal cycle length for a short-term main line is often about two weeks.

Sometimes shorter.

Sometimes longer.

But generally it’s about that level.

So when you look at medical now, don’t use that kind of very naive way to think:

“Will it be able to keep boarding tomorrow?”

“If it shook today, is it already over?”

“If there wasn’t broad market up today, is it weak?”

What you need to look at is:

Is this line still in its cycle right now?

Is it in the middle-to-late part of the main advance, or has it already completely exhausted?

Has the high banner become isolated already?

Has sector spreading already broken down?

As long as these core questions haven’t completely gone bad, you can’t sentence the main line to death with one句话.

So the most objective view on medical now is:

It’s no longer in the very initial launch stage.

But it hasn’t yet shown hard evidence that it has fully ended.

Why?

Because the high banner is still there.

The first board is still there.

The sector is still red.

The elastic names are still there.

Follow-through is still there in the front row.

Spreading is still there.

This shows that although the cycle has moved forward for a while, it’s not yet time for a “direct final verdict.”

What do leaders really look at? Today I’m going to break this logic down for you.

Doing it as a leader trader isn’t about staring at a single stock all day.

A leader trader watches a structure.

This structure has at least four layers:

1. Is the leader itself still strong, and does it have follow-through/acceptance? After divergence, can it stand its ground? Does it get废 the moment it’s smashed?

2. Is there still a first board within the sector? This is the most important. If there’s a first board, there’s spreading. If there’s spreading, it means it’s not only a single crowd anymore.

3. Do the little brothers and the front row continue to follow? If only the high banner is strong by itself, that’s dangerous. If the front row is still pushing forward, it means the sector temperature is still there.

4. Do elastic names and the mid-band have coordination? A 10cm leader board—20cm elasticity is moving too, and the mid-band is stable—then this line isn’t “deadly locked crowding together,” but has layers.

Why can’t medical be easily called “over” today?

Because in these four layers, none is completely collapsing.

For players using different models, there really isn’t any need to “exchange” like this—this too I’ll explain along the way.

Many disputes in trading aren’t essentially about different viewpoints.

It’s about different models.

Those who play first boards focus on the first moment.

Those who trade as leaders focus on space and identifiers.

Those who trade trends focus on mid-band follow-through.

Those who buy on dips focus on post-divergence repair.

Those who do arbitrage focus on next-day premium.

Those who trade swings focus on daily chart structure.

Everyone isn’t looking at the same thing.

So why force communication?

I say this: this first board from Xintian Pharmaceutical is important.

A leader trader understands it as: this is a sector-spreading signal.

A first-board trader hears: can this trade be hit?

A dip buyer hears: if it pulls back tomorrow, can it be bought?

A trend trader hears: does this stock have capacity?

It’s just not the same thing.

So going forward, don’t use one model’s language to force-fit another model.

A lot of ineffective communication comes from exactly this.

You ask me what my circling means.

I’ll answer you with one line:

I circled the sector signal, not a buy-point instruction.

Once you understand this sentence, the trading layer will improve by a lot.

Next, how to observe medical—I’ll break it down into three layers for you directly.

1. Post-close observation conclusion
   Medical is still one of the strong lines in the current market.
   This isn’t because JinYao Pharmaceutical boarded one more day.
   Instead, because:

The leader is still there
The first board is still there
The sector is still red
The elastic names are still there
The front row is still following
This means the structure hasn’t broken.

2. Conditions to watch the next day
   What do you watch tomorrow? It’s simple: just these three:

After divergence, JinYao Pharmaceutical can’t directly get A-slashed (quickly destroyed)
The medical sector still needs new first boards, second boards, or continued assists from the front row
20cm elasticity and the mid-band direction can’t collectively go out (turn off)

As long as the first two of these three are still intact, the medical line can’t be said to be completely over.

3. When is the real invalidation signal actually dangerous?
   I only recognize these:

No more first-board limit-ups within the sector; the spreading breaks down
After the high-position divergence of the leader, the re-close clearly lacks strength
The front row fully falls out; only one high banner is hard-supporting
A new main line appears, and funds are clearly pulled out

Only when it reaches this point is when you should truly be on high alert.

Remember one sentence:

The leader doesn’t die at the height.

The leader usually dies when it loses the sector.

Last, one most realistic thing:

Many people don’t dare to buy the leader, feeling that leaders have gone up a lot—so much, so fast, so quickly—there’s no comfortable buy point.

But reality is exactly the opposite.

The leader goes up a lot, but falls slowly.

The back row goes up less, but falls hard.

Most people are apparently pursuing safety.

In practice, they’re buying a worse risk-reward tradeoff.

That’s why after a full round of a market cycle, the ones who truly make money are always the group that can identify the core, accept divergence, and follow the strongest direction in the sector.

Not because they’re bold.

It’s because they can see more clearly.

Today, with this medical line, the market has already said it plainly:

Our medical judgment is still correct.

But even more important: don’t just know how to shout “correct.”

You have to know:

Why it’s correct.

How much longer it can stay correct.

Under what circumstances it stops being correct.

When the leader should be held, and when it should be left.

What the first-board signal is really telling you.

These things are the truly valuable parts in trading.

Core conclusion 1) This medical line hasn’t finished yet; at least today there’s no hard evidence that it has ended.
2) Our view on medical continues to be validated by the market.
3) The leader’s true selling point is not that it has gone up too much, but that the sector is no longer spreading.
4) Big divergence after consecutive limit-ups is normal; doing as a leader requires a strong heart.
5) When I circle a first board, it doesn’t mean you should go buy it; I’m just checking whether there’s still anyone in the sector continuing to ignite.

Disclaimer
This article is only compiled market-public information, post-tape review, and trading-thought discussion, and does not constitute any investment advice. The market has risk; trading requires independent judgment, and risk is borne by you. The individual stocks and sectors mentioned in the article are only used as examples for market analysis, not as specific buy/sell grounds.
Interactive question
Do you think now the most critical observation point for this medical line is the stock itself—JinYao Pharmaceutical—or whether the sector can still keep冒出 first boards afterwards? Welcome to leave your judgment in the comments.
If this article helps you, please tap the “In the know” and like button and send a small love heart at the bottom right, and feel free to share it with people who need it. If you have any questions, leave them in the comments—I will answer everything I can.
Keywords medical, innovative drugs, JinYao Pharmaceutical, Xintian Pharmaceutical, leader trading strategy, sector effect, first board, consecutive limit-up divergence, short-term post-tape review, A-share main line